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ART roll-out is bringing many benefits to infected individ-
uals in the resource-poor world. A large number of studies
on ART use in the developed world have informed our
understanding on the determinants of ART success and
implications of failure. However, there are a number of
differences between resource-rich and -poor environ-
ments which will impact on the nature of HIV drug resist-
ance. Firstly, virological monitoring (viral load and
resistance testing) is unlikely to accompany much roll-
out. Thus, treatment switch will be guided more by clini-
cal, than virological/immunological criteria. Secondly,
increasing use of MTCTP will lead to resistance in infected
mothers and children, prior to instigating long term ART.
Thirdly, the limited first- and second-line treatment
options will impact on the clinical implications of emerg-
ing resistance. These three issues, as well as others, will
determine the levels of emerging resistance in treated indi-
viduals, and thus the degree to which transmission of such
resistance will occur. I will review the data on all these
issues, and describe some of the surveillance structures in
place to monitor rates of resistance.
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